In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva buys Teva Marion interest from Aventis

Executive Summary

Israeli generics company Teva Pharmaceutical will acquire the remaining interest of Teva Marion Partners from Aventis. The 50/50 joint venture was originally set up in 1995 by Hoechst's Marion Merrell Dow division--before the merger of Hoechst and Rhone-Poulenc created Aventis--to market the injectable multiple sclerosis drug Copaxone (glatiramer acetate).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition

Related Companies